speb/financial-data huggingface dataset:
RX.V cash_flow (annual, 2024-12-31) — Net PPE Purchase And Sale: -42282.00
RX.V balance_sheet (annual, 2024-12-31) — Net Tangible Assets: 29961684.00
RX.V balance_sheet (annual, 2024-12-31) — Non Current Deferred Assets: 401166.00
RX.V balance_sheet (annual, 2024-12-31) — Non Current Deferred Liabilities: 110055.00
RX.V balance_sheet (annual, 2024-12-31) — Non Current Deferred Taxes Assets: 401166.00
RX.V balance_sheet (annual, 2024-12-31) — Non Current Deferred Taxes Liabilities: 110055.00
RX.V balance_sheet (annual, 2024-12-31) — Non Current Note Receivables: 141140.00
RX.V income_statement (annual, 2024-12-31) — Normalized EBITDA: 10742853.00
RX.V income_statement (annual, 2024-12-31) — Normalized Income: 7501420.81
RX.V cash_flow (annual, 2024-12-31) — Operating Cash Flow: 8663484.00
RX.V cash_flow (annual, 2024-12-31) — Operating Gains Losses: -33075.00
RX.V income_statement (annual, 2024-12-31) — Operating Income: 9064319.00
RX.V income_statement (annual, 2024-12-31) — Operating Revenue: 35030897.00
RX.V balance_sheet (annual, 2024-12-31) — Ordinary Shares Number: 11282017.00
RX.V income_statement (annual, 2024-12-31) — Other Gand A: 1703333.00
RX.V income_statement (annual, 2024-12-31) — Other Income Expense: -311255.00
RX.V balance_sheet (annual, 2024-12-31) — Other Intangible Assets: 5041501.00
RX.V cash_flow (annual, 2024-12-31) — Other Non Cash Items: -1042722.00
RX.V income_statement (annual, 2024-12-31) — Other Operating Expenses: 248681.00
RX.V income_statement (quarterly, 2024-12-31) — Other Operating Expenses: 55850.00
RX.V balance_sheet (annual, 2024-12-31) — Other Properties: 266367.00
RX.V balance_sheet (annual, 2024-12-31) — Other Receivables: 34191.00
RX.V balance_sheet (annual, 2024-12-31) — Other Short Term Investments: 3827595.00
RX.V balance_sheet (annual, 2024-12-31) — Payables: 4395281.00
RX.V balance_sheet (annual, 2024-12-31) — Payables And Accrued Expenses: 4395281.00
RX.V balance_sheet (annual, 2024-12-31) — Prepaid Assets: 201971.00
RX.V income_statement (annual, 2024-12-31) — Pretax Income: 9782498.00
RX.V cash_flow (annual, 2024-12-31) — Proceeds From Stock Option Exercised: 250388.00
RX.V balance_sheet (annual, 2024-12-31) — Properties: 0.00
RX.V income_statement (annual, 2024-12-31) — Provision For Doubtful Accounts: 136491.00
RX.V income_statement (quarterly, 2024-12-31) — Provision For Doubtful Accounts: 136491.00
RX.V cash_flow (annual, 2024-12-31) — Provisionand Write Offof Assets: 136491.00
RX.V cash_flow (quarterly, 2024-12-31) — Provisionand Write Offof Assets: 136491.00
RX.V cash_flow (annual, 2024-12-31) — Purchase Of Intangibles: -4627369.00
RX.V cash_flow (annual, 2024-12-31) — Purchase Of Investment: -7603571.00
RX.V cash_flow (quarterly, 2024-12-31) — Purchase Of Investment: 393142.00
RX.V cash_flow (annual, 2024-12-31) — Purchase Of PPE: -42282.00
RX.V balance_sheet (annual, 2024-12-31) — Raw Materials: 981253.00
RX.V balance_sheet (annual, 2024-12-31) — Receivables: 2994262.00
RX.V income_statement (annual, 2024-12-31) — Reconciled Cost Of Revenue: 7174824.00
RX.V income_statement (annual, 2024-12-31) — Reconciled Depreciation: 589948.00
RX.V cash_flow (annual, 2024-12-31) — Repayment Of Debt: -183314.00
RX.V cash_flow (annual, 2024-12-31) — Repurchase Of Capital Stock: -5176660.00
RX.V income_statement (annual, 2024-12-31) — Research And Development: 171373.00
RX.V balance_sheet (annual, 2024-12-31) — Retained Earnings: 27729011.00
RX.V income_statement (annual, 2024-12-31) — Salaries And Wages: 8886595.00
RX.V cash_flow (annual, 2024-12-31) — Sale Of Investment: 14374882.00
RX.V cash_flow (quarterly, 2024-12-31) — Sale Of Investment: 455827.00
RX.V income_statement (annual, 2024-12-31) — Selling And Marketing Expense: 6851806.00
RX.V income_statement (annual, 2024-12-31) — Selling General And Administration: 17645261.00
RX.V balance_sheet (annual, 2024-12-31) — Share Issued: 11489216.00
RX.V income_statement (annual, 2024-12-31) — Special Income Charges: -430016.00
RX.V cash_flow (annual, 2024-12-31) — Stock Based Compensation: 553521.00
RX.V balance_sheet (annual, 2024-12-31) — Stockholders Equity: 35003185.00
RX.V balance_sheet (annual, 2024-12-31) — Tangible Book Value: 29961684.00
RX.V income_statement (annual, 2024-12-31) — Tax Effect Of Unusual Items: -79938.19
RX.V income_statement (annual, 2024-12-31) — Tax Provision: 2512394.00
RX.V income_statement (annual, 2024-12-31) — Tax Rate For Calcs: 0.26
RX.V balance_sheet (annual, 2024-12-31) — Total Assets: 41359450.00
RX.V balance_sheet (annual, 2024-12-31) — Total Capitalization: 35003185.00
RX.V balance_sheet (annual, 2024-12-31) — Total Debt: 1037731.00
RX.V balance_sheet (annual, 2024-12-31) — Total Equity Gross Minority Interest: 35003185.00
RX.V income_statement (annual, 2024-12-31) — Total Expenses: 25966578.00
RX.V balance_sheet (annual, 2024-12-31) — Total Liabilities Net Minority Interest: 6356265.00
RX.V balance_sheet (annual, 2024-12-31) — Total Non Current Assets: 16888370.00
RX.V balance_sheet (annual, 2024-12-31) — Total Non Current Liabilities Net Minority Interest: 951159.00
RX.V income_statement (annual, 2024-12-31) — Total Operating Income As Reported: 8753064.00
RX.V balance_sheet (annual, 2024-12-31) — Total Tax Payable: 396343.00
RX.V income_statement (annual, 2024-12-31) — Total Unusual Items: -311255.00
RX.V income_statement (annual, 2024-12-31) — Total Unusual Items Excluding Goodwill: -311255.00
RX.V balance_sheet (annual, 2024-12-31) — Treasury Shares Number: 207199.00
RX.V balance_sheet (annual, 2024-12-31) — Working Capital: 19065974.00
RX.V income_statement (quarterly, 2025-03-31) — +Operating Expense: 5388596.00
RX.V income_statement (quarterly, 2025-03-31) — +Total Revenue: 10978960.00
RX.V balance_sheet (quarterly, 2025-03-31) — Accounts Payable: 4756311.00
RX.V balance_sheet (quarterly, 2025-03-31) — Accounts Receivable: 4482091.00
RX.V balance_sheet (quarterly, 2025-03-31) — Accrued Interest Receivable: 589666.00
RX.V balance_sheet (quarterly, 2025-03-31) — Accumulated Depreciation: -2231801.00
RX.V balance_sheet (quarterly, 2025-03-31) — Additional Paid In Capital: 1774998.00
RX.V income_statement (quarterly, 2025-03-31) — Amortization: 144276.00
RX.V cash_flow (quarterly, 2025-03-31) — Amortization Cash Flow: 144276.00
RX.V cash_flow (quarterly, 2025-03-31) — Amortization Of Intangibles: 144276.00
RX.V income_statement (quarterly, 2025-03-31) — Amortization Of Intangibles Income Statement: 144276.00
RX.V income_statement (quarterly, 2025-03-31) — Basic Average Shares: 11269162.00
RX.V income_statement (quarterly, 2025-03-31) — Basic EPS: 0.21
RX.V cash_flow (quarterly, 2025-03-31) — Beginning Cash Position: 12113376.00
RX.V balance_sheet (quarterly, 2025-03-31) — Buildings And Improvements: 1330455.00
RX.V cash_flow (quarterly, 2025-03-31) — Capital Expenditure: -88357.00
RX.V balance_sheet (quarterly, 2025-03-31) — Capital Lease Obligations: 990218.00
RX.V balance_sheet (quarterly, 2025-03-31) — Capital Stock: 5139237.00
RX.V balance_sheet (quarterly, 2025-03-31) — Cash And Cash Equivalents: 10953615.00
RX.V balance_sheet (quarterly, 2025-03-31) — Cash Cash Equivalents And Short Term Investments: 17401557.00
RX.V cash_flow (quarterly, 2025-03-31) — Cash Dividends Paid: -563311.00
RX.V balance_sheet (quarterly, 2025-03-31) — Cash Equivalents: 2508137.00
RX.V balance_sheet (quarterly, 2025-03-31) — Cash Financial: 8445478.00
RX.V cash_flow (quarterly, 2025-03-31) — Cash Flow From Continuing Financing Activities: -1521003.00
RX.V cash_flow (quarterly, 2025-03-31) — Cash Flow From Continuing Investing Activities: 1080311.00
RX.V cash_flow (quarterly, 2025-03-31) — Cash Flow From Continuing Operating Activities: -718398.00
RX.V cash_flow (quarterly, 2025-03-31) — Change In Account Payable: 757373.00
RX.V cash_flow (quarterly, 2025-03-31) — Change In Income Tax Payable: 360217.00
RX.V cash_flow (quarterly, 2025-03-31) — Change In Inventory: 50844.00
RX.V cash_flow (quarterly, 2025-03-31) — Change In Other Working Capital: -689881.00
RX.V cash_flow (quarterly, 2025-03-31) — Change In Payable: 1117590.00
RX.V cash_flow (quarterly, 2025-03-31) — Change In Payables And Accrued Expense: 1117590.00
RX.V cash_flow (quarterly, 2025-03-31) — Change In Prepaid Assets: -282683.00
RX.V cash_flow (quarterly, 2025-03-31) — Change In Receivables: -3467863.00
RX.V cash_flow (quarterly, 2025-03-31) — Change In Tax Payable: 360217.00
RX.V cash_flow (quarterly, 2025-03-31) — Change In Working Capital: -3271993.00
RX.V cash_flow (quarterly, 2025-03-31) — Changes In Cash: -1159090.00
RX.V balance_sheet (quarterly, 2025-03-31) — Common Stock: 5139237.00
RX.V cash_flow (quarterly, 2025-03-31) — Common Stock Dividend Paid: -563311.00
RX.V balance_sheet (quarterly, 2025-03-31) — Common Stock Equity: 36011796.00
RX.V cash_flow (quarterly, 2025-03-31) — Common Stock Payments: -668780.00
RX.V income_statement (quarterly, 2025-03-31) — Cost Of Revenue: 2641768.00
RX.V balance_sheet (quarterly, 2025-03-31) — Current Assets: 28642114.00
RX.V balance_sheet (quarterly, 2025-03-31) — Current Capital Lease Obligation: 201806.00
RX.V balance_sheet (quarterly, 2025-03-31) — Current Debt And Capital Lease Obligation: 201806.00
RX.V balance_sheet (quarterly, 2025-03-31) — Current Deferred Liabilities: 123316.00
RX.V balance_sheet (quarterly, 2025-03-31) — Current Deferred Revenue: 123316.00
RX.V balance_sheet (quarterly, 2025-03-31) — Current Liabilities: 5846653.00
RX.V cash_flow (quarterly, 2025-03-31) — Deferred Income Tax: 26226.00
RX.V cash_flow (quarterly, 2025-03-31) — Deferred Tax: 26226.00
RX.V cash_flow (quarterly, 2025-03-31) — Depreciation: 66907.00
RX.V cash_flow (quarterly, 2025-03-31) — Depreciation Amortization Depletion: 211183.00
RX.V income_statement (quarterly, 2025-03-31) — Depreciation Amortization Depletion Income Statement: 211183.00
RX.V cash_flow (quarterly, 2025-03-31) — Depreciation And Amortization: 211183.00
RX.V income_statement (quarterly, 2025-03-31) — Depreciation And Amortization In Income Statement: 211183.00
RX.V income_statement (quarterly, 2025-03-31) — Depreciation Income Statement: 66907.00
RX.V income_statement (quarterly, 2025-03-31) — Diluted Average Shares: 11515873.00
RX.V income_statement (quarterly, 2025-03-31) — Diluted EPS: 0.20
RX.V income_statement (quarterly, 2025-03-31) — Diluted NI Availto Com Stockholders: 2319933.00
RX.V income_statement (quarterly, 2025-03-31) — EBIT: 3169474.00
RX.V income_statement (quarterly, 2025-03-31) — EBITDA: 3380657.00
RX.V cash_flow (quarterly, 2025-03-31) — Effect Of Exchange Rate Changes: -671.00
RX.V cash_flow (quarterly, 2025-03-31) — End Cash Position: 10953615.00
RX.V cash_flow (quarterly, 2025-03-31) — Financing Cash Flow: -1521003.00
RX.V balance_sheet (quarterly, 2025-03-31) — Finished Goods: 4044440.00
RX.V balance_sheet (quarterly, 2025-03-31) — Foreign Currency Translation Adjustments: -172225.00
RX.V cash_flow (quarterly, 2025-03-31) — Free Cash Flow: -806755.00
RX.V cash_flow (quarterly, 2025-03-31) — Gain Loss On Investment Securities: 14450.00
RX.V income_statement (quarterly, 2025-03-31) — Gain On Sale Of Security: 41868.00
RX.V balance_sheet (quarterly, 2025-03-31) — Gains Losses Not Affecting Retained Earnings: -172225.00
RX.V income_statement (quarterly, 2025-03-31) — General And Administrative Expense: 3265309.00
RX.V balance_sheet (quarterly, 2025-03-31) — Goodwill And Other Intangible Assets: 4965682.00
RX.V balance_sheet (quarterly, 2025-03-31) — Gross PPE: 3385786.00
RX.V income_statement (quarterly, 2025-03-31) — Gross Profit: 8337192.00
RX.V balance_sheet (quarterly, 2025-03-31) — Hedging Assets Current: 0.00
RX.V balance_sheet (quarterly, 2025-03-31) — Held To Maturity Securities: 7497025.00
RX.V cash_flow (quarterly, 2025-03-31) — Income Tax Paid Supplemental Data: 449996.00
RX.V balance_sheet (quarterly, 2025-03-31) — Income Tax Payable: 756560.00
RX.V income_statement (quarterly, 2025-03-31) — Insurance And Claims: 62770.00
RX.V income_statement (quarterly, 2025-03-31) — Interest Expense: 13103.00
RX.V income_statement (quarterly, 2025-03-31) — Interest Expense Non Operating: 13103.00
RX.V income_statement (quarterly, 2025-03-31) — Interest Income: 179010.00
RX.V income_statement (quarterly, 2025-03-31) — Interest Income Non Operating: 179010.00
RX.V cash_flow (quarterly, 2025-03-31) — Interest Paid Cff: -13103.00
RX.V cash_flow (quarterly, 2025-03-31) — Interest Received Cfi: 1127044.00
RX.V balance_sheet (quarterly, 2025-03-31) — Inventory: 5277242.00
RX.V balance_sheet (quarterly, 2025-03-31) — Invested Capital: 36011796.00
RX.V cash_flow (quarterly, 2025-03-31) — Investing Cash Flow: 1080311.00
RX.V balance_sheet (quarterly, 2025-03-31) — Investmentin Financial Assets: 7497025.00
RX.V balance_sheet (quarterly, 2025-03-31) — Investments And Advances: 7497025.00
RX.V cash_flow (quarterly, 2025-03-31) — Issuance Of Debt: 0.00
RX.V balance_sheet (quarterly, 2025-03-31) — Leases: 680511.00
RX.V balance_sheet (quarterly, 2025-03-31) — Loans Receivable: 52004.00
RX.V balance_sheet (quarterly, 2025-03-31) — Long Term Capital Lease Obligation: 788412.00
RX.V balance_sheet (quarterly, 2025-03-31) — Long Term Debt And Capital Lease Obligation: 788412.00
RX.V cash_flow (quarterly, 2025-03-31) — Long Term Debt Payments: -47513.00
RX.V balance_sheet (quarterly, 2025-03-31) — Machinery Furniture Equipment: 1108453.00
RX.V cash_flow (quarterly, 2025-03-31) — Net Business Purchase And Sale: 0.00
RX.V cash_flow (quarterly, 2025-03-31) — Net Common Stock Issuance: -668780.00
RX.V income_statement (quarterly, 2025-03-31) — Net Income: 2319933.00
RX.V income_statement (quarterly, 2025-03-31) — Net Income Common Stockholders: 2319933.00
RX.V income_statement (quarterly, 2025-03-31) — Net Income Continuous Operations: 2319933.00
RX.V income_statement (quarterly, 2025-03-31) — Net Income From Continuing And Discontinued Operation: 2319933.00
RX.V income_statement (quarterly, 2025-03-31) — Net Income From Continuing Operation Net Minority Interest: 2319933.00
RX.V cash_flow (quarterly, 2025-03-31) — Net Income From Continuing Operations: 2319933.00
RX.V income_statement (quarterly, 2025-03-31) — Net Income Including Noncontrolling Interests: 2319933.00
RX.V cash_flow (quarterly, 2025-03-31) — Net Intangibles Purchase And Sale: -68457.00
RX.V income_statement (quarterly, 2025-03-31) — Net Interest Income: 165907.00
RX.V cash_flow (quarterly, 2025-03-31) — Net Investment Purchase And Sale: -13801.00
RX.V cash_flow (quarterly, 2025-03-31) — Net Issuance Payments Of Debt: -47513.00
RX.V cash_flow (quarterly, 2025-03-31) — Net Long Term Debt Issuance: -47513.00
RX.V income_statement (quarterly, 2025-03-31) — Net Non Operating Interest Income Expense: 165907.00
RX.V cash_flow (quarterly, 2025-03-31) — Net Other Financing Charges: -286834.00
RX.V cash_flow (quarterly, 2025-03-31) — Net Other Investing Changes: 55425.00
RX.V balance_sheet (quarterly, 2025-03-31) — Net PPE: 1153985.00
RX.V cash_flow (quarterly, 2025-03-31) — Net PPE Purchase And Sale: -19900.00
RX.V cash_flow (quarterly, 2025-03-31) — Net Short Term Debt Issuance: 0.00
RX.V balance_sheet (quarterly, 2025-03-31) — Net Tangible Assets: 31046114.00
RX.V balance_sheet (quarterly, 2025-03-31) — Non Current Deferred Assets: 380206.00
RX.V balance_sheet (quarterly, 2025-03-31) — Non Current Deferred Liabilities: 115321.00
RX.V balance_sheet (quarterly, 2025-03-31) — Non Current Deferred Taxes Assets: 380206.00
RX.V balance_sheet (quarterly, 2025-03-31) — Non Current Deferred Taxes Liabilities: 115321.00
RX.V balance_sheet (quarterly, 2025-03-31) — Non Current Note Receivables: 123170.00
RX.V income_statement (quarterly, 2025-03-31) — Normalized EBITDA: 3338789.00
RX.V income_statement (quarterly, 2025-03-31) — Normalized Income: 2289160.02
RX.V cash_flow (quarterly, 2025-03-31) — Operating Cash Flow: -718398.00
RX.V cash_flow (quarterly, 2025-03-31) — Operating Gains Losses: 14450.00
RX.V income_statement (quarterly, 2025-03-31) — Operating Income: 2948596.00
RX.V income_statement (quarterly, 2025-03-31) — Operating Revenue: 10978960.00
RX.V balance_sheet (quarterly, 2025-03-31) — Ordinary Shares Number: 11254189.00
RX.V balance_sheet (quarterly, 2025-03-31) — Other Current Liabilities: 8660.00
RX.V income_statement (quarterly, 2025-03-31) — Other Gand A: 621194.00
RX.V income_statement (quarterly, 2025-03-31) — Other Income Expense: 41868.00
RX.V balance_sheet (quarterly, 2025-03-31) — Other Intangible Assets: 4965682.00
RX.V cash_flow (quarterly, 2025-03-31) — Other Non Cash Items: -167933.00
RX.V income_statement (quarterly, 2025-03-31) — Other Operating Expenses: 54789.00
RX.V balance_sheet (quarterly, 2025-03-31) — Other Properties: 266367.00
RX.V balance_sheet (quarterly, 2025-03-31) — Other Receivables: 354900.00
RX.V balance_sheet (quarterly, 2025-03-31) — Other Short Term Investments: 6447942.00
RX.V balance_sheet (quarterly, 2025-03-31) — Payables: 5512871.00
RX.V balance_sheet (quarterly, 2025-03-31) — Payables And Accrued Expenses: 5512871.00
RX.V balance_sheet (quarterly, 2025-03-31) — Prepaid Assets: 484654.00
RX.V income_statement (quarterly, 2025-03-31) — Pretax Income: 3156371.00
RX.V cash_flow (quarterly, 2025-03-31) — Proceeds From Stock Option Exercised: 58538.00
RX.V balance_sheet (quarterly, 2025-03-31) — Properties: 0.00
RX.V income_statement (quarterly, 2025-03-31) — Provision For Doubtful Accounts: 0.00
RX.V cash_flow (quarterly, 2025-03-31) — Provisionand Write Offof Assets: 0.00
RX.V cash_flow (quarterly, 2025-03-31) — Purchase Of Business: 0.00
RX.V cash_flow (quarterly, 2025-03-31) — Purchase Of Intangibles: -68457.00
RX.V cash_flow (quarterly, 2025-03-31) — Purchase Of Investment: -2620347.00
RX.V cash_flow (quarterly, 2025-03-31) — Purchase Of PPE: -19900.00
RX.V balance_sheet (quarterly, 2025-03-31) — Raw Materials: 1232802.00
RX.V balance_sheet (quarterly, 2025-03-31) — Receivables: 5478661.00
RX.V income_statement (quarterly, 2025-03-31) — Reconciled Cost Of Revenue: 2641768.00
RX.V income_statement (quarterly, 2025-03-31) — Reconciled Depreciation: 211183.00
RX.V cash_flow (quarterly, 2025-03-31) — Repayment Of Debt: -47513.00
RX.V cash_flow (quarterly, 2025-03-31) — Repurchase Of Capital Stock: -668780.00
RX.V income_statement (quarterly, 2025-03-31) — Research And Development: 89380.00
RX.V income_statement (quarterly, 2025-03-31) — Restructuring And Mergern Acquisition: 0.00
RX.V balance_sheet (quarterly, 2025-03-31) — Retained Earnings: 29269786.00
RX.V income_statement (quarterly, 2025-03-31) — Salaries And Wages: 2581345.00
RX.V cash_flow (quarterly, 2025-03-31) — Sale Of Investment: 2606546.00
RX.V income_statement (quarterly, 2025-03-31) — Selling And Marketing Expense: 1822724.00
RX.V income_statement (quarterly, 2025-03-31) — Selling General And Administration: 5088033.00
RX.V balance_sheet (quarterly, 2025-03-31) — Share Issued: 11470672.00
RX.V cash_flow (quarterly, 2025-03-31) — Short Term Debt Issuance: 0.00
RX.V cash_flow (quarterly, 2025-03-31) — Short Term Debt Payments: 0.00
RX.V income_statement (quarterly, 2025-03-31) — Special Income Charges: 0.00
RX.V cash_flow (quarterly, 2025-03-31) — Stock Based Compensation: 149736.00
RX.V balance_sheet (quarterly, 2025-03-31) — Stockholders Equity: 36011796.00
RX.V balance_sheet (quarterly, 2025-03-31) — Tangible Book Value: 31046114.00
RX.V income_statement (quarterly, 2025-03-31) — Tax Effect Of Unusual Items: 11095.02
RX.V income_statement (quarterly, 2025-03-31) — Tax Provision: 836438.00
RX.V income_statement (quarterly, 2025-03-31) — Tax Rate For Calcs: 0.27
RX.V balance_sheet (quarterly, 2025-03-31) — Total Assets: 42762182.00
RX.V balance_sheet (quarterly, 2025-03-31) — Total Capitalization: 36011796.00
RX.V balance_sheet (quarterly, 2025-03-31) — Total Debt: 990218.00
RX.V balance_sheet (quarterly, 2025-03-31) — Total Equity Gross Minority Interest: 36011796.00
RX.V income_statement (quarterly, 2025-03-31) — Total Expenses: 8030364.00
RX.V balance_sheet (quarterly, 2025-03-31) — Total Liabilities Net Minority Interest: 6750386.00
RX.V balance_sheet (quarterly, 2025-03-31) — Total Non Current Assets: 14120068.00
RX.V balance_sheet (quarterly, 2025-03-31) — Total Non Current Liabilities Net Minority Interest: 903733.00
RX.V income_statement (quarterly, 2025-03-31) — Total Operating Income As Reported: 2990464.00
RX.V balance_sheet (quarterly, 2025-03-31) — Total Tax Payable: 756560.00
RX.V income_statement (quarterly, 2025-03-31) — Total Unusual Items: 41868.00
RX.V income_statement (quarterly, 2025-03-31) — Total Unusual Items Excluding Goodwill: 41868.00
RX.V balance_sheet (quarterly, 2025-03-31) — Treasury Shares Number: 216483.00
RX.V balance_sheet (quarterly, 2025-03-31) — Working Capital: 22795461.00
RX.V income_statement (quarterly, 2025-06-30) — +Operating Expense: 5345965.00
RX.V income_statement (quarterly, 2025-06-30) — +Total Revenue: 10179296.00
RX.V balance_sheet (quarterly, 2025-06-30) — Accounts Payable: 3805661.00
RX.V balance_sheet (quarterly, 2025-06-30) — Accounts Receivable: 4248145.00
RX.V balance_sheet (quarterly, 2025-06-30) — Accrued Interest Receivable: 583796.00
RX.V balance_sheet (quarterly, 2025-06-30) — Accumulated Depreciation: -2299876.00
RX.V balance_sheet (quarterly, 2025-06-30) — Additional Paid In Capital: 1891951.00
RX.V income_statement (quarterly, 2025-06-30) — Amortization: 144566.00
RX.V cash_flow (quarterly, 2025-06-30) — Amortization Cash Flow: 144566.00
RX.V cash_flow (quarterly, 2025-06-30) — Amortization Of Intangibles: 144566.00
RX.V income_statement (quarterly, 2025-06-30) — Amortization Of Intangibles Income Statement: 144566.00
RX.V income_statement (quarterly, 2025-06-30) — Basic Average Shares: 11254689.00
RX.V income_statement (quarterly, 2025-06-30) — Basic EPS: 0.18
RX.V cash_flow (quarterly, 2025-06-30) — Beginning Cash Position: 10953615.00
RX.V balance_sheet (quarterly, 2025-06-30) — Buildings And Improvements: 1330455.00
RX.V cash_flow (quarterly, 2025-06-30) — Capital Expenditure: -43769.00
RX.V balance_sheet (quarterly, 2025-06-30) — Capital Lease Obligations: 942232.00
RX.V balance_sheet (quarterly, 2025-06-30) — Capital Stock: 5173592.00
RX.V balance_sheet (quarterly, 2025-06-30) — Cash And Cash Equivalents: 13948895.00
RX.V balance_sheet (quarterly, 2025-06-30) — Cash Cash Equivalents And Short Term Investments: 20364392.00
RX.V cash_flow (quarterly, 2025-06-30) — Cash Dividends Paid: -562732.00
RX.V balance_sheet (quarterly, 2025-06-30) — Cash Equivalents: 3538835.00
RX.V balance_sheet (quarterly, 2025-06-30) — Cash Financial: 10410060.00
RX.V cash_flow (quarterly, 2025-06-30) — Cash Flow From Continuing Financing Activities: -640568.00
RX.V cash_flow (quarterly, 2025-06-30) — Cash Flow From Continuing Investing Activities: 171694.00
RX.V cash_flow (quarterly, 2025-06-30) — Cash Flow From Continuing Operating Activities: 3471120.00
RX.V cash_flow (quarterly, 2025-06-30) — Change In Account Payable: -950650.00
RX.V cash_flow (quarterly, 2025-06-30) — Change In Income Tax Payable: -563962.00
RX.V cash_flow (quarterly, 2025-06-30) — Change In Inventory: 416629.00
RX.V cash_flow (quarterly, 2025-06-30) — Change In Other Working Capital: 700785.00
RX.V cash_flow (quarterly, 2025-06-30) — Change In Payable: -1514612.00
RX.V cash_flow (quarterly, 2025-06-30) — Change In Payables And Accrued Expense: -1514612.00
RX.V cash_flow (quarterly, 2025-06-30) — Change In Prepaid Assets: 41081.00
RX.V cash_flow (quarterly, 2025-06-30) — Change In Receivables: 1623350.00
RX.V cash_flow (quarterly, 2025-06-30) — Change In Tax Payable: -563962.00
RX.V cash_flow (quarterly, 2025-06-30) — Change In Working Capital: 1267233.00
RX.V cash_flow (quarterly, 2025-06-30) — Changes In Cash: 3002246.00
RX.V balance_sheet (quarterly, 2025-06-30) — Common Stock: 5173592.00
RX.V balance_sheet (quarterly, 2025-06-30) — Common Stock Equity: 37600753.00
RX.V cash_flow (quarterly, 2025-06-30) — Common Stock Payments: 0.00
RX.V income_statement (quarterly, 2025-06-30) — Cost Of Revenue: 2266734.00
RX.V balance_sheet (quarterly, 2025-06-30) — Current Assets: 30592472.00
RX.V balance_sheet (quarterly, 2025-06-30) — Current Capital Lease Obligation: 207081.00
RX.V balance_sheet (quarterly, 2025-06-30) — Current Debt And Capital Lease Obligation: 207081.00
RX.V balance_sheet (quarterly, 2025-06-30) — Current Deferred Liabilities: 824103.00
RX.V balance_sheet (quarterly, 2025-06-30) — Current Deferred Revenue: 824103.00
RX.V balance_sheet (quarterly, 2025-06-30) — Current Liabilities: 5042364.00
RX.V cash_flow (quarterly, 2025-06-30) — Deferred Income Tax: 11002.00
RX.V cash_flow (quarterly, 2025-06-30) — Deferred Tax: 11002.00
RX.V cash_flow (quarterly, 2025-06-30) — Depreciation: 68075.00
RX.V cash_flow (quarterly, 2025-06-30) — Depreciation Amortization Depletion: 212641.00
RX.V income_statement (quarterly, 2025-06-30) — Depreciation Amortization Depletion Income Statement: 212641.00
RX.V cash_flow (quarterly, 2025-06-30) — Depreciation And Amortization: 212641.00
RX.V income_statement (quarterly, 2025-06-30) — Depreciation And Amortization In Income Statement: 212641.00
RX.V income_statement (quarterly, 2025-06-30) — Depreciation Income Statement: 68075.00
RX.V income_statement (quarterly, 2025-06-30) — Diluted Average Shares: 11498898.00
RX.V income_statement (quarterly, 2025-06-30) — Diluted EPS: 0.18
RX.V income_statement (quarterly, 2025-06-30) — Diluted NI Availto Com Stockholders: 2018171.00
RX.V income_statement (quarterly, 2025-06-30) — EBIT: 2758442.00
RX.V income_statement (quarterly, 2025-06-30) — EBITDA: 2971083.00
RX.V cash_flow (quarterly, 2025-06-30) — Effect Of Exchange Rate Changes: -6966.00
RX.V cash_flow (quarterly, 2025-06-30) — End Cash Position: 13948895.00
RX.V cash_flow (quarterly, 2025-06-30) — Financing Cash Flow: -640568.00
RX.V balance_sheet (quarterly, 2025-06-30) — Finished Goods: 3993938.00
RX.V balance_sheet (quarterly, 2025-06-30) — Foreign Currency Translation Adjustments: -179191.00
RX.V cash_flow (quarterly, 2025-06-30) — Free Cash Flow: 3427351.00
RX.V cash_flow (quarterly, 2025-06-30) — Gain Loss On Investment Securities: 4261.00
RX.V income_statement (quarterly, 2025-06-30) — Gain On Sale Of Security: -19089.00
RX.V balance_sheet (quarterly, 2025-06-30) — Gains Losses Not Affecting Retained Earnings: -179191.00
RX.V income_statement (quarterly, 2025-06-30) — General And Administrative Expense: 2965497.00
RX.V balance_sheet (quarterly, 2025-06-30) — Goodwill And Other Intangible Assets: 4846156.00
RX.V balance_sheet (quarterly, 2025-06-30) — Gross PPE: 3404515.00
RX.V income_statement (quarterly, 2025-06-30) — Gross Profit: 7912562.00
RX.V balance_sheet (quarterly, 2025-06-30) — Hedging Assets Current: 0.00
RX.V balance_sheet (quarterly, 2025-06-30) — Held To Maturity Securities: 6497025.00
RX.V cash_flow (quarterly, 2025-06-30) — Income Tax Paid Supplemental Data: 470387.00
RX.V balance_sheet (quarterly, 2025-06-30) — Income Tax Payable: 192598.00
RX.V income_statement (quarterly, 2025-06-30) — Insurance And Claims: 54148.00
RX.V income_statement (quarterly, 2025-06-30) — Interest Expense: 12631.00
RX.V income_statement (quarterly, 2025-06-30) — Interest Expense Non Operating: 12631.00
RX.V income_statement (quarterly, 2025-06-30) — Interest Income: 210934.00
RX.V income_statement (quarterly, 2025-06-30) — Interest Income Non Operating: 210934.00
RX.V cash_flow (quarterly, 2025-06-30) — Interest Paid Cff: -12631.00
RX.V cash_flow (quarterly, 2025-06-30) — Interest Received Cfi: -853553.00
RX.V balance_sheet (quarterly, 2025-06-30) — Inventory: 4860613.00
RX.V balance_sheet (quarterly, 2025-06-30) — Invested Capital: 37600753.00
RX.V cash_flow (quarterly, 2025-06-30) — Investing Cash Flow: 171694.00
RX.V balance_sheet (quarterly, 2025-06-30) — Investmentin Financial Assets: 6497025.00
RX.V balance_sheet (quarterly, 2025-06-30) — Investments And Advances: 6497025.00
RX.V balance_sheet (quarterly, 2025-06-30) — Leases: 680511.00
RX.V balance_sheet (quarterly, 2025-06-30) — Loans Receivable: 56098.00
RX.V balance_sheet (quarterly, 2025-06-30) — Long Term Capital Lease Obligation: 735151.00
RX.V balance_sheet (quarterly, 2025-06-30) — Long Term Debt And Capital Lease Obligation: 735151.00
RX.V cash_flow (quarterly, 2025-06-30) — Long Term Debt Payments: -47986.00
RX.V balance_sheet (quarterly, 2025-06-30) — Machinery Furniture Equipment: 1117445.00
RX.V cash_flow (quarterly, 2025-06-30) — Net Common Stock Issuance: 0.00
RX.V income_statement (quarterly, 2025-06-30) — Net Income: 2018171.00
RX.V income_statement (quarterly, 2025-06-30) — Net Income Common Stockholders: 2018171.00
RX.V income_statement (quarterly, 2025-06-30) — Net Income Continuous Operations: 2018171.00
RX.V income_statement (quarterly, 2025-06-30) — Net Income From Continuing And Discontinued Operation: 2018171.00
RX.V income_statement (quarterly, 2025-06-30) — Net Income From Continuing Operation Net Minority Interest: 2018171.00
RX.V cash_flow (quarterly, 2025-06-30) — Net Income From Continuing Operations: 2018171.00
RX.V income_statement (quarterly, 2025-06-30) — Net Income Including Noncontrolling Interests: 2018171.00
RX.V cash_flow (quarterly, 2025-06-30) — Net Intangibles Purchase And Sale: -25040.00
RX.V income_statement (quarterly, 2025-06-30) — Net Interest Income: 198303.00
RX.V cash_flow (quarterly, 2025-06-30) — Net Investment Purchase And Sale: 1032445.00
RX.V cash_flow (quarterly, 2025-06-30) — Net Issuance Payments Of Debt: -47986.00
RX.V cash_flow (quarterly, 2025-06-30) — Net Long Term Debt Issuance: -47986.00
RX.V income_statement (quarterly, 2025-06-30) — Net Non Operating Interest Income Expense: 198303.00
RX.V cash_flow (quarterly, 2025-06-30) — Net Other Financing Charges: -23505.00
RX.V cash_flow (quarterly, 2025-06-30) — Net Other Investing Changes: 36571.00
RX.V balance_sheet (quarterly, 2025-06-30) — Net PPE: 1104639.00
RX.V cash_flow (quarterly, 2025-06-30) — Net PPE Purchase And Sale: -18729.00
RX.V balance_sheet (quarterly, 2025-06-30) — Net Tangible Assets: 32754597.00
RX.V balance_sheet (quarterly, 2025-06-30) — Non Current Deferred Assets: 371104.00
RX.V balance_sheet (quarterly, 2025-06-30) — Non Current Deferred Liabilities: 117221.00
RX.V balance_sheet (quarterly, 2025-06-30) — Non Current Deferred Taxes Assets: 371104.00
RX.V balance_sheet (quarterly, 2025-06-30) — Non Current Deferred Taxes Liabilities: 117221.00
RX.V balance_sheet (quarterly, 2025-06-30) — Non Current Note Receivables: 84093.00
RX.V income_statement (quarterly, 2025-06-30) — Normalized EBITDA: 2990172.00
RX.V income_statement (quarterly, 2025-06-30) — Normalized Income: 2032201.41
RX.V cash_flow (quarterly, 2025-06-30) — Operating Cash Flow: 3471120.00
RX.V cash_flow (quarterly, 2025-06-30) — Operating Gains Losses: 4261.00
RX.V income_statement (quarterly, 2025-06-30) — Operating Income: 2566597.00
RX.V income_statement (quarterly, 2025-06-30) — Operating Revenue: 10179296.00
RX.V balance_sheet (quarterly, 2025-06-30) — Ordinary Shares Number: 11257057.00
RX.V balance_sheet (quarterly, 2025-06-30) — Other Current Liabilities: 12921.00
RX.V income_statement (quarterly, 2025-06-30) — Other Gand A: 461665.00
RX.V income_statement (quarterly, 2025-06-30) — Other Income Expense: -19089.00
RX.V balance_sheet (quarterly, 2025-06-30) — Other Intangible Assets: 4846156.00
RX.V cash_flow (quarterly, 2025-06-30) — Other Non Cash Items: -199891.00
RX.V income_statement (quarterly, 2025-06-30) — Other Operating Expenses: 48301.00
RX.V balance_sheet (quarterly, 2025-06-30) — Other Properties: 276104.00
RX.V balance_sheet (quarterly, 2025-06-30) — Other Receivables: 35855.00
RX.V balance_sheet (quarterly, 2025-06-30) — Other Short Term Investments: 6415497.00
RX.V balance_sheet (quarterly, 2025-06-30) — Payables: 3998259.00
RX.V balance_sheet (quarterly, 2025-06-30) — Payables And Accrued Expenses: 3998259.00
RX.V balance_sheet (quarterly, 2025-06-30) — Prepaid Assets: 443573.00
RX.V income_statement (quarterly, 2025-06-30) — Pretax Income: 2745811.00
RX.V cash_flow (quarterly, 2025-06-30) — Proceeds From Stock Option Exercised: 6286.00
RX.V balance_sheet (quarterly, 2025-06-30) — Properties: 0.00
RX.V cash_flow (quarterly, 2025-06-30) — Purchase Of Intangibles: -25040.00
RX.V cash_flow (quarterly, 2025-06-30) — Purchase Of PPE: -18729.00
RX.V balance_sheet (quarterly, 2025-06-30) — Raw Materials: 866675.00
RX.V balance_sheet (quarterly, 2025-06-30) — Receivables: 4923894.00
RX.V income_statement (quarterly, 2025-06-30) — Reconciled Cost Of Revenue: 2266734.00
RX.V income_statement (quarterly, 2025-06-30) — Reconciled Depreciation: 212641.00
RX.V cash_flow (quarterly, 2025-06-30) — Repayment Of Debt: -47986.00
RX.V cash_flow (quarterly, 2025-06-30) — Repurchase Of Capital Stock: 0.00
RX.V income_statement (quarterly, 2025-06-30) — Research And Development: 47944.00
RX.V balance_sheet (quarterly, 2025-06-30) — Retained Earnings: 30714401.00
RX.V income_statement (quarterly, 2025-06-30) — Salaries And Wages: 2449684.00
RX.V income_statement (quarterly, 2025-06-30) — Selling And Marketing Expense: 2071582.00
RX.V income_statement (quarterly, 2025-06-30) — Selling General And Administration: 5037079.00
RX.V balance_sheet (quarterly, 2025-06-30) — Share Issued: 11471686.00
RX.V cash_flow (quarterly, 2025-06-30) — Stock Based Compensation: 157703.00
RX.V balance_sheet (quarterly, 2025-06-30) — Stockholders Equity: 37600753.00
RX.V balance_sheet (quarterly, 2025-06-30) — Tangible Book Value: 32754597.00
RX.V income_statement (quarterly, 2025-06-30) — Tax Effect Of Unusual Items: -5058.59
RX.V income_statement (quarterly, 2025-06-30) — Tax Provision: 727640.00
RX.V income_statement (quarterly, 2025-06-30) — Tax Rate For Calcs: 0.27
RX.V balance_sheet (quarterly, 2025-06-30) — Total Assets: 43495489.00
RX.V balance_sheet (quarterly, 2025-06-30) — Total Capitalization: 37600753.00
RX.V balance_sheet (quarterly, 2025-06-30) — Total Debt: 942232.00
RX.V balance_sheet (quarterly, 2025-06-30) — Total Equity Gross Minority Interest: 37600753.00
RX.V income_statement (quarterly, 2025-06-30) — Total Expenses: 7612699.00
RX.V balance_sheet (quarterly, 2025-06-30) — Total Liabilities Net Minority Interest: 5894736.00
RX.V balance_sheet (quarterly, 2025-06-30) — Total Non Current Assets: 12903017.00
RX.V balance_sheet (quarterly, 2025-06-30) — Total Non Current Liabilities Net Minority Interest: 852372.00
RX.V income_statement (quarterly, 2025-06-30) — Total Operating Income As Reported: 2547508.00
RX.V balance_sheet (quarterly, 2025-06-30) — Total Tax Payable: 192598.00
RX.V income_statement (quarterly, 2025-06-30) — Total Unusual Items: -19089.00
RX.V income_statement (quarterly, 2025-06-30) — Total Unusual Items Excluding Goodwill: -19089.00
RX.V balance_sheet (quarterly, 2025-06-30) — Treasury Shares Number: 214629.00
RX.V balance_sheet (quarterly, 2025-06-30) — Working Capital: 25550108.00
RX.V income_statement (quarterly, 2025-09-30) — +Operating Expense: 5858225.00
RX.V income_statement (quarterly, 2025-09-30) — +Total Revenue: 12221804.00
RX.V balance_sheet (quarterly, 2025-09-30) — Accounts Payable: 6406739.00
RX.V balance_sheet (quarterly, 2025-09-30) — Accounts Receivable: 5533582.00
RX.V balance_sheet (quarterly, 2025-09-30) — Accrued Interest Receivable: 689793.00
RX.V balance_sheet (quarterly, 2025-09-30) — Accumulated Depreciation: -2366229.00
RX.V balance_sheet (quarterly, 2025-09-30) — Additional Paid In Capital: 2011666.00
RX.V income_statement (quarterly, 2025-09-30) — Amortization: 135852.00
RX.V cash_flow (quarterly, 2025-09-30) — Amortization Cash Flow: 135852.00
RX.V cash_flow (quarterly, 2025-09-30) — Amortization Of Intangibles: 135852.00
RX.V income_statement (quarterly, 2025-09-30) — Amortization Of Intangibles Income Statement: 135852.00
RX.V income_statement (quarterly, 2025-09-30) — Basic Average Shares: 11260451.00
RX.V income_statement (quarterly, 2025-09-30) — Basic EPS: 0.24
RX.V cash_flow (quarterly, 2025-09-30) — Beginning Cash Position: 13948895.00
RX.V balance_sheet (quarterly, 2025-09-30) — Buildings And Improvements: 1330455.00
RX.V cash_flow (quarterly, 2025-09-30) — Capital Expenditure: -240319.00
RX.V balance_sheet (quarterly, 2025-09-30) — Capital Lease Obligations: 892878.00
RX.V balance_sheet (quarterly, 2025-09-30) — Capital Stock: 5240446.00
RX.V balance_sheet (quarterly, 2025-09-30) — Cash And Cash Equivalents: 16568691.00
RX.V balance_sheet (quarterly, 2025-09-30) — Cash Cash Equivalents And Short Term Investments: 23395434.00
RX.V cash_flow (quarterly, 2025-09-30) — Cash Dividends Paid: -563065.00
RX.V balance_sheet (quarterly, 2025-09-30) — Cash Equivalents: 2539835.00
RX.V balance_sheet (quarterly, 2025-09-30) — Cash Financial: 14028856.00
RX.V cash_flow (quarterly, 2025-09-30) — Cash Flow From Continuing Financing Activities: -607042.00
RX.V cash_flow (quarterly, 2025-09-30) — Cash Flow From Continuing Investing Activities: 450869.00
RX.V cash_flow (quarterly, 2025-09-30) — Cash Flow From Continuing Operating Activities: 2768990.00
RX.V cash_flow (quarterly, 2025-09-30) — Change In Inventory: -1038751.00
RX.V cash_flow (quarterly, 2025-09-30) — Change In Other Working Capital: -748479.00
RX.V cash_flow (quarterly, 2025-09-30) — Change In Payables And Accrued Expense: 2804823.00
RX.V cash_flow (quarterly, 2025-09-30) — Change In Prepaid Assets: 103635.00
RX.V cash_flow (quarterly, 2025-09-30) — Change In Receivables: -1184358.00
RX.V cash_flow (quarterly, 2025-09-30) — Change In Working Capital: -63130.00
RX.V cash_flow (quarterly, 2025-09-30) — Changes In Cash: 2612817.00
RX.V balance_sheet (quarterly, 2025-09-30) — Common Stock: 5240446.00
RX.V balance_sheet (quarterly, 2025-09-30) — Common Stock Equity: 39902869.00
RX.V cash_flow (quarterly, 2025-09-30) — Common Stock Payments: -327173.00
RX.V income_statement (quarterly, 2025-09-30) — Cost Of Revenue: 2954884.00
RX.V balance_sheet (quarterly, 2025-09-30) — Current Assets: 35969294.00
RX.V balance_sheet (quarterly, 2025-09-30) — Current Capital Lease Obligation: 211575.00
RX.V balance_sheet (quarterly, 2025-09-30) — Current Debt And Capital Lease Obligation: 211575.00
RX.V balance_sheet (quarterly, 2025-09-30) — Current Deferred Liabilities: 161504.00
RX.V balance_sheet (quarterly, 2025-09-30) — Current Deferred Revenue: 161504.00
RX.V balance_sheet (quarterly, 2025-09-30) — Current Liabilities: 7106740.00
RX.V cash_flow (quarterly, 2025-09-30) — Deferred Income Tax: 5993.00
RX.V cash_flow (quarterly, 2025-09-30) — Deferred Tax: 5993.00
RX.V cash_flow (quarterly, 2025-09-30) — Depreciation: 66353.00
RX.V cash_flow (quarterly, 2025-09-30) — Depreciation Amortization Depletion: 202205.00
RX.V income_statement (quarterly, 2025-09-30) — Depreciation Amortization Depletion Income Statement: 202205.00
RX.V cash_flow (quarterly, 2025-09-30) — Depreciation And Amortization: 202205.00
RX.V income_statement (quarterly, 2025-09-30) — Depreciation And Amortization In Income Statement: 202205.00
RX.V income_statement (quarterly, 2025-09-30) — Depreciation Income Statement: 66353.00
RX.V income_statement (quarterly, 2025-09-30) — Diluted Average Shares: 11503514.00
RX.V income_statement (quarterly, 2025-09-30) — Diluted EPS: 0.23
RX.V income_statement (quarterly, 2025-09-30) — Diluted NI Availto Com Stockholders: 2682340.00
RX.V income_statement (quarterly, 2025-09-30) — EBIT: 3661583.00
RX.V income_statement (quarterly, 2025-09-30) — EBITDA: 3863788.00
RX.V cash_flow (quarterly, 2025-09-30) — Effect Of Exchange Rate Changes: 6979.00
RX.V cash_flow (quarterly, 2025-09-30) — End Cash Position: 16568691.00
RX.V cash_flow (quarterly, 2025-09-30) — Financing Cash Flow: -607042.00
RX.V balance_sheet (quarterly, 2025-09-30) — Finished Goods: 3887121.00
RX.V balance_sheet (quarterly, 2025-09-30) — Foreign Currency Translation Adjustments: -172212.00
RX.V cash_flow (quarterly, 2025-09-30) — Free Cash Flow: 2528671.00
RX.V cash_flow (quarterly, 2025-09-30) — Gain Loss On Investment Securities: 3539.00
RX.V income_statement (quarterly, 2025-09-30) — Gain On Sale Of Security: 21499.00
RX.V balance_sheet (quarterly, 2025-09-30) — Gains Losses Not Affecting Retained Earnings: -172212.00
RX.V income_statement (quarterly, 2025-09-30) — General And Administrative Expense: 3039514.00
RX.V balance_sheet (quarterly, 2025-09-30) — Goodwill And Other Intangible Assets: 4948931.00
RX.V balance_sheet (quarterly, 2025-09-30) — Gross PPE: 3406207.00
RX.V income_statement (quarterly, 2025-09-30) — Gross Profit: 9266920.00
RX.V balance_sheet (quarterly, 2025-09-30) — Hedging Assets Current: 0.00
RX.V balance_sheet (quarterly, 2025-09-30) — Held To Maturity Securities: 5400816.00
RX.V cash_flow (quarterly, 2025-09-30) — Income Tax Paid Supplemental Data: 126607.00
RX.V balance_sheet (quarterly, 2025-09-30) — Income Tax Payable: 310462.00
RX.V income_statement (quarterly, 2025-09-30) — Insurance And Claims: 43824.00
RX.V income_statement (quarterly, 2025-09-30) — Interest Expense: 12141.00
RX.V income_statement (quarterly, 2025-09-30) — Interest Expense Non Operating: 12141.00
RX.V income_statement (quarterly, 2025-09-30) — Interest Income: 231389.00
RX.V income_statement (quarterly, 2025-09-30) — Interest Income Non Operating: 231389.00
RX.V cash_flow (quarterly, 2025-09-30) — Interest Paid Cff: -12141.00
RX.V cash_flow (quarterly, 2025-09-30) — Interest Received Cfi: 6225.00
RX.V balance_sheet (quarterly, 2025-09-30) — Inventory: 5899364.00
RX.V balance_sheet (quarterly, 2025-09-30) — Invested Capital: 39902869.00
RX.V cash_flow (quarterly, 2025-09-30) — Investing Cash Flow: 450869.00
RX.V balance_sheet (quarterly, 2025-09-30) — Investmentin Financial Assets: 5400816.00
RX.V balance_sheet (quarterly, 2025-09-30) — Investments And Advances: 5400816.00
RX.V balance_sheet (quarterly, 2025-09-30) — Leases: 680511.00
RX.V balance_sheet (quarterly, 2025-09-30) — Loans Receivable: 57240.00
RX.V balance_sheet (quarterly, 2025-09-30) — Long Term Capital Lease Obligation: 681303.00
RX.V balance_sheet (quarterly, 2025-09-30) — Long Term Debt And Capital Lease Obligation: 681303.00
RX.V cash_flow (quarterly, 2025-09-30) — Long Term Debt Payments: -49354.00
RX.V balance_sheet (quarterly, 2025-09-30) — Machinery Furniture Equipment: 1117902.00
RX.V cash_flow (quarterly, 2025-09-30) — Net Common Stock Issuance: -327173.00
RX.V income_statement (quarterly, 2025-09-30) — Net Income: 2682340.00
RX.V income_statement (quarterly, 2025-09-30) — Net Income Common Stockholders: 2682340.00
RX.V income_statement (quarterly, 2025-09-30) — Net Income Continuous Operations: 2682340.00
RX.V income_statement (quarterly, 2025-09-30) — Net Income From Continuing And Discontinued Operation: 2682340.00
RX.V income_statement (quarterly, 2025-09-30) — Net Income From Continuing Operation Net Minority Interest: 2682340.00
RX.V cash_flow (quarterly, 2025-09-30) — Net Income From Continuing Operations: 2682340.00
RX.V income_statement (quarterly, 2025-09-30) — Net Income Including Noncontrolling Interests: 2682340.00
RX.V cash_flow (quarterly, 2025-09-30) — Net Intangibles Purchase And Sale: -238627.00
RX.V income_statement (quarterly, 2025-09-30) — Net Interest Income: 219248.00
RX.V cash_flow (quarterly, 2025-09-30) — Net Investment Purchase And Sale: 684963.00
RX.V cash_flow (quarterly, 2025-09-30) — Net Issuance Payments Of Debt: -49354.00
RX.V cash_flow (quarterly, 2025-09-30) — Net Long Term Debt Issuance: -49354.00
RX.V income_statement (quarterly, 2025-09-30) — Net Non Operating Interest Income Expense: 219248.00
RX.V cash_flow (quarterly, 2025-09-30) — Net Other Investing Changes: 0.00
RX.V balance_sheet (quarterly, 2025-09-30) — Net PPE: 1039978.00
RX.V cash_flow (quarterly, 2025-09-30) — Net PPE Purchase And Sale: -1692.00
RX.V balance_sheet (quarterly, 2025-09-30) — Net Tangible Assets: 34953938.00
RX.V balance_sheet (quarterly, 2025-09-30) — Non Current Deferred Assets: 342359.00
RX.V balance_sheet (quarterly, 2025-09-30) — Non Current Deferred Liabilities: 94469.00
RX.V balance_sheet (quarterly, 2025-09-30) — Non Current Deferred Taxes Assets: 342359.00
RX.V balance_sheet (quarterly, 2025-09-30) — Non Current Deferred Taxes Liabilities: 94469.00
RX.V balance_sheet (quarterly, 2025-09-30) — Non Current Note Receivables: 84003.00
RX.V income_statement (quarterly, 2025-09-30) — Normalized EBITDA: 3842289.00
RX.V income_statement (quarterly, 2025-09-30) — Normalized Income: 2666538.23
RX.V cash_flow (quarterly, 2025-09-30) — Operating Cash Flow: 2768990.00
RX.V cash_flow (quarterly, 2025-09-30) — Operating Gains Losses: 3539.00
RX.V income_statement (quarterly, 2025-09-30) — Operating Income: 3408695.00
RX.V income_statement (quarterly, 2025-09-30) — Operating Revenue: 12221804.00
RX.V balance_sheet (quarterly, 2025-09-30) — Ordinary Shares Number: 11262282.00
RX.V balance_sheet (quarterly, 2025-09-30) — Other Current Liabilities: 16460.00
RX.V income_statement (quarterly, 2025-09-30) — Other Gand A: 520129.00
RX.V income_statement (quarterly, 2025-09-30) — Other Income Expense: 21499.00
RX.V balance_sheet (quarterly, 2025-09-30) — Other Intangible Assets: 4948931.00
RX.V cash_flow (quarterly, 2025-09-30) — Other Non Cash Items: -220301.00
RX.V income_statement (quarterly, 2025-09-30) — Other Operating Expenses: 357329.00
RX.V balance_sheet (quarterly, 2025-09-30) — Other Properties: 277339.00
RX.V balance_sheet (quarterly, 2025-09-30) — Other Receivables: 53943.00
RX.V balance_sheet (quarterly, 2025-09-30) — Other Short Term Investments: 6826743.00
RX.V balance_sheet (quarterly, 2025-09-30) — Payables: 6717201.00
RX.V balance_sheet (quarterly, 2025-09-30) — Payables And Accrued Expenses: 6717201.00
RX.V balance_sheet (quarterly, 2025-09-30) — Prepaid Assets: 339938.00
RX.V income_statement (quarterly, 2025-09-30) — Pretax Income: 3649442.00
RX.V cash_flow (quarterly, 2025-09-30) — Proceeds From Stock Option Exercised: 34352.00
RX.V balance_sheet (quarterly, 2025-09-30) — Properties: 0.00
RX.V cash_flow (quarterly, 2025-09-30) — Purchase Of Intangibles: -238627.00
RX.V cash_flow (quarterly, 2025-09-30) — Purchase Of PPE: -1692.00
RX.V balance_sheet (quarterly, 2025-09-30) — Raw Materials: 2012243.00
RX.V balance_sheet (quarterly, 2025-09-30) — Receivables: 6334558.00
RX.V income_statement (quarterly, 2025-09-30) — Reconciled Cost Of Revenue: 2954884.00
RX.V income_statement (quarterly, 2025-09-30) — Reconciled Depreciation: 202205.00
RX.V cash_flow (quarterly, 2025-09-30) — Repayment Of Debt: -49354.00
RX.V cash_flow (quarterly, 2025-09-30) — Repurchase Of Capital Stock: -327173.00
RX.V income_statement (quarterly, 2025-09-30) — Research And Development: 127500.00
RX.V balance_sheet (quarterly, 2025-09-30) — Retained Earnings: 32822969.00
RX.V income_statement (quarterly, 2025-09-30) — Salaries And Wages: 2475561.00
RX.V income_statement (quarterly, 2025-09-30) — Selling And Marketing Expense: 2131677.00
RX.V income_statement (quarterly, 2025-09-30) — Selling General And Administration: 5171191.00
RX.V balance_sheet (quarterly, 2025-09-30) — Share Issued: 11475447.00
RX.V cash_flow (quarterly, 2025-09-30) — Stock Based Compensation: 158344.00
RX.V balance_sheet (quarterly, 2025-09-30) — Stockholders Equity: 39902869.00
RX.V balance_sheet (quarterly, 2025-09-30) — Tangible Book Value: 34953938.00
RX.V income_statement (quarterly, 2025-09-30) — Tax Effect Of Unusual Items: 5697.23
RX.V income_statement (quarterly, 2025-09-30) — Tax Provision: 967102.00
RX.V income_statement (quarterly, 2025-09-30) — Tax Rate For Calcs: 0.27
RX.V balance_sheet (quarterly, 2025-09-30) — Total Assets: 47785381.00
RX.V balance_sheet (quarterly, 2025-09-30) — Total Capitalization: 39902869.00
RX.V balance_sheet (quarterly, 2025-09-30) — Total Debt: 892878.00
RX.V balance_sheet (quarterly, 2025-09-30) — Total Equity Gross Minority Interest: 39902869.00
RX.V income_statement (quarterly, 2025-09-30) — Total Expenses: 8813109.00
RX.V balance_sheet (quarterly, 2025-09-30) — Total Liabilities Net Minority Interest: 7882512.00
RX.V balance_sheet (quarterly, 2025-09-30) — Total Non Current Assets: 11816087.00
RX.V balance_sheet (quarterly, 2025-09-30) — Total Non Current Liabilities Net Minority Interest: 775772.00
RX.V income_statement (quarterly, 2025-09-30) — Total Operating Income As Reported: 3430194.00
RX.V balance_sheet (quarterly, 2025-09-30) — Total Tax Payable: 310462.00
RX.V income_statement (quarterly, 2025-09-30) — Total Unusual Items: 21499.00
RX.V income_statement (quarterly, 2025-09-30) — Total Unusual Items Excluding Goodwill: 21499.00
RX.V balance_sheet (quarterly, 2025-09-30) — Treasury Shares Number: 213165.00
RX.V balance_sheet (quarterly, 2025-09-30) — Working Capital: 28862554.00
RX.V income_statement (annual, 2025-12-31) — +Operating Expense: 21649874.00
RX.V income_statement (quarterly, 2025-12-31) — +Operating Expense: 5057088.00
RX.V income_statement (annual, 2025-12-31) — +Total Revenue: 43051983.00
RX.V income_statement (quarterly, 2025-12-31) — +Total Revenue: 9671923.00